Equities Analysts Set Expectations for VTGN Q1 Earnings

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) – Analysts at William Blair issued their Q1 2027 earnings estimates for VistaGen Therapeutics in a report released on Wednesday, June 18th. William Blair analyst M. Minter anticipates that the company will earn ($0.37) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for VistaGen Therapeutics’ current full-year earnings is ($1.77) per share. William Blair also issued estimates for VistaGen Therapeutics’ Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.48) EPS and Q4 2027 earnings at ($0.41) EPS.

VistaGen Therapeutics Price Performance

NASDAQ:VTGN opened at $2.00 on Thursday. The firm has a market capitalization of $58.32 million, a P/E ratio of -1.20 and a beta of 0.70. VistaGen Therapeutics has a 1-year low of $1.90 and a 1-year high of $4.21. The company’s fifty day moving average price is $2.31 and its 200-day moving average price is $2.57.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Tuesday, June 17th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.10. The firm had revenue of ($0.01) million for the quarter, compared to analyst estimates of $0.18 million. VistaGen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 58.88%. During the same quarter in the prior year, the business earned ($0.25) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Blair William & Co. IL increased its holdings in VistaGen Therapeutics by 11.3% in the fourth quarter. Blair William & Co. IL now owns 98,466 shares of the company’s stock valued at $290,000 after buying an additional 10,000 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in VistaGen Therapeutics in the first quarter valued at $25,000. Two Sigma Advisers LP purchased a new position in VistaGen Therapeutics in the fourth quarter valued at $35,000. Millennium Management LLC increased its holdings in VistaGen Therapeutics by 52.9% in the fourth quarter. Millennium Management LLC now owns 38,732 shares of the company’s stock valued at $114,000 after buying an additional 13,395 shares in the last quarter. Finally, Man Group plc purchased a new position in VistaGen Therapeutics in the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.